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Key questions
What is already known about this subject?
 ► Large multicentre trials show that catheter ablation 
for ventricular tachycardia (VT) is an effective and 
relatively safe therapy.
 ► The demand for VT ablation is growing due to in-
creased survival of patients with myocardial infarc-
tion and a lower threshold for patient selection.
What does this study add?
 ► This real-world study confirms VT ablation is safe 
and associated with high acute procedural success 
and long-term outcomes comparable with ran-
domised controlled studies.
How might this impact on clinical practice?
 ► This study provides evidence that an established 
ablation centre can deliver similar clinical outcomes 
(efficacy and safety) to those reported in large mul-
ticentre studies.
ABSTRACT
Background Ventricular tachycardia (VT) is associated 
with increased morbidity and mortality. There is growing 
evidence for the effectiveness of catheter ablation 
in improving outcomes in patients with recurrent VT. 
Consequently the threshold for referral for VT ablation has 
fallen over recent years, resulting in increased number of 
procedures.
Objective To evaluate the effectiveness and safety of VT 
ablation in a real-world tertiary centre setting.
Methods This is a prospective analysis of all VT ablation 
cases performed at University Hospital Coventry. Follow-
up data were obtained from review of electronic medical 
records and patient interview. The primary endpoint for 
normal heart VT was death, cardiovascular hospitalisation 
and VT recurrence, and for structural heart VT was 
arrhythmic death, VT storm (>3 episodes within 24 hours) 
or appropriate shock.
Results Forty-seven patients underwent 53 procedures 
from January 2012 to January 2018. The mean age ±SD 
was 57±15 years, 68% were male, 81% were Caucasian 
and 66% were elective cases. The aetiology of VT 
included normal heart (49%), ischaemic cardiomyopathy 
(ICM, 36%), dilated cardiomyopathy (9%), hypertrophic 
cardiomyopathy (4%) and valvular heart disease (2%). 
Procedural success occurred in 83%, with six major 
complications. After a median follow-up of 231 days 
(lower quartile 133, upper quartile 631), the primary 
outcome occurred in 28% of patients. There were two 
non-arrhythmic deaths (4%). At a median follow-up of 193 
days (129–468), the primary outcome occurred in 19% 
of patients with ICM, while VT storm/appropriate shocks 
occurred in three patients (17%).
Conclusions Our real-world registry confirms that 
VT ablation is safe, and is associated with high acute 
procedural success and long-term outcomes comparable 
with randomised controlled studies.
IntROduCtIOn
Ventricular tachycardia (VT) results in 
significant morbidity, and in patients with 
structural heart disease (SHD) (including 
prior myocardial infarction) is associated 
with increased risk of sudden cardiac death 
(SCD).1 2 In myocardial infarction survi-
vors the risk of SCD can be reduced with 
implantable cardioverter defibrillator (ICD) 
implantation.3 While ICDs are effective in 
terminating VT and aborting SCD, they do 
not prevent ventricular arrhythmias. Given 
that ICD shocks are associated with reduced 
quality of life and increased mortality,4 strat-
egies are sought to prevent VT and minimise 
shocks. VT does not appear to significantly 
increase mortality in patients with structur-
ally normal hearts, but can result in signifi-
cant symptoms and cardiac dysfunction in 
patients with a high burden.5 Antiarrhythmic 
drugs (AADs) and catheter ablation have 
not been shown to improve mortality but 
do prevent recurrent VT in patients with or 
without ICDs.1 6 7 Despite their efficacy, AADs 
have an unfavourable safety profile, including 
proarrhythmia and extracardiac toxicity, 
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Figure 1 ICM ablation workflow demonstrating mapping 
strategies employed. (A) Endocardial substrate map with 
(i) bipolar scar definition <1.5 mV and dense scar <0.5 mV 
and (ii) unipolar scar definition <8.0 mV. Septal and lateral 
views of the LV are shown, with grey scar extending from 
the lateral LV wall apical and inferior with the extensive basal 
septal scar. (B) Activation map of the right bundle branch 
block morphology VT TCL 544 ms. Mid-diastolic potentials 
were seen at the basal anterolateral LV (black arrow) shown 
as early meets late. (C) Entrainment mapping (i) from the 
basal anterolateral LV showing entrainment with concealed 
fusion (pace map 12/12), a postpacing interval (555 ms) 
minus TCL (544 ms) of 11 ms and stimulus to QRS of 103 
ms. (C) Restoration of sinus rhythm during ablation (ii) with 
acute procedural success confirmed with non-inducibility 
(iii). ICM, ischaemic cardiomyopathy; LV, left ventricle; TCL, 
tachycardia cycle length; VT, ventricular tachycardia.
particularly associated with long-term amiodarone use.6 
Catheter ablation for VT directly targets and alters the 
arrhythmia substrate,8–12 reducing the need for AADs.
In patients with SHD, catheter ablation has tradition-
ally been reserved for patients with advanced cardiac 
disease and drug refractory VT.13 14 However, in patients 
with ischaemic cardiomyopathy (ICM), accumulating 
evidence supports earlier intervention with catheter abla-
tion.7 15 16 Techniques for VT ablation have developed to 
allow for successful mapping and ablation of unstable 
VTs.10 12 16 17 As a result, the threshold to refer patients 
for VT ablation has fallen over recent years. Randomised 
control trials (RCTs) have recruited patients into large 
centres with extensive experience demonstrating the 
superiority of VT ablation over medical therapy; however, 
there are limited real-world data on the efficacy and 
safety of catheter ablation for VT in developing centres. 
We report our contemporary single-centre experience for 
VT ablation since the emergence of distinct patient selec-
tion criteria and advances in mapping and ablation tech-
nologies. In addition, we performed a substudy analysis 
on the efficacy and safety of patients with ICM compared 
with normal heart VT (nhVT). We hypothesised that our 
efficacy and safety would be comparable with that seen in 
contemporary RCTs.
MetHOds
study design
Detailed methodology can be found in the online supple-
mentary material. Briefly, patients who underwent cath-
eter ablation for VT performed at the University Hospital 
Coventry from January 2012 to January 2018 were prospec-
tively entered into a registry. For nhVT (structurally 
normal heart on transthoracic echocardiogram or cardiac 
MRI, or cardiac dysfunction attributed to high premature 
ventricular contraction (PVC) burden), referral criteria 
included symptomatic VT despite medical therapy; intol-
erance to medication or patient preference against medi-
cation; PVC burden >10%; and cardiac dysfunction. For 
structural heart VT (shVT, ICM or non-ICM), indications 
included symptomatic VT despite medical therapy; three 
or more episodes of VT within 24 hours; at least three 
episodes of VT requiring antitachycardia pacing (ATP); 
or at least one appropriate defibrillator shock.
Procedures
All nhVT ablation procedures were performed under 
conscious sedation and selective shVT ablation proce-
dures under general anaesthesia, where procedural risk 
was deemed high. Oral anticoagulation with warfarin 
was uninterrupted (target international normalised ratio 
2.0–3.0). Direct oral anticoagulants were omitted on the 
day of the procedure. Anticoagulation was resumed the 
same day provided there were no significant bleeding 
events. When available a 12-lead ECG during VT was 
used to guide chamber mapping. Clinical VT induction 
was attempted with programmed electrical stimulation 
(PES). Patients were allowed to remain in VT during 
mapping and ablation if haemodynamically stable; other-
wise VT was terminated with ATP or electrical direct 
current cardioversion. Electroanatomical substrate and 
activation mapping was performed using the EnSite 
NAVX/Velocity/Precision (Abbott Medical, Minneap-
olis, Minnesota) systems or CARTO 3 (Biosense Webster, 
Diamond Bar, California). All nhVT cases underwent 
pace mapping,11 and if VT was haemodynamically stable 
activation mapping was performed. For shVT a combi-
nation of substrate mapping, pace mapping and activa-
tion/entrainment mapping was performed, as shown 
in figure 1. The critical isthmus, late potentials, local 
abnormal ventricular activities (LAVA) potentials and 
decrementing early/late potentials were identified.8 9 
Unstable VT mapping and ablation were performed using 
a substrate modification approach,12 16 using a range of 
catheters including conventional and saline-irrigated 
ablation catheters (≤8 mm tips) (online supplementary 
table 1). Power, force-time integral, lesion size index 
and ablation index settings were at the operator’s discre-
tion. At the end of the procedure, standardised PES 
was performed. Complete acute procedural success was 
defined as termination of clinical VT with failure to 
induce clinical VT or VT with a longer tachycardia cycle 
length (TCL). To minimise follow-up bias, postproce-
dure ICD therapies (ATP/shock) were programmed 
according to a standardised protocol on the basis of the 
best evidence available.18 19
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Figure 2 Cumulative frequency of ventricular tachycardia 
ablation procedures performed.
Outcomes
Follow-up was calculated from the first procedure until 
the last documented clinical contact after the VT abla-
tion. The primary outcome for nhVT was a composite 
endpoint including all-cause death, cardiovascular 
hospitalisation and recurrent VT (defined as sponta-
neous sustained VT, or Holter evidence of PVC burden 
>10%). For shVT the primary outcome was a composite 
endpoint including arrhythmic death, appropriate shock 
or VT storm (defined as three or more documented 
VT episodes occurring within 24 hours). Secondary 
outcomes included all-cause death, appropriate shock, 
recurrent VT, VT storm and cardiovascular hospitalisa-
tion. A substudy analysis was performed to compare VT 
ablation outcomes between patients with nhVT and ICM.
statistical analyses
Statistical analyses were performed using SPSS V.22. 
Group differences were tested using Pearson’s χ2 test 
for categorical variables, and independent t-tests or 
Wilcoxon test for continuous variables. P<0.05 was statis-
tically significant.
Results
Baseline demographics
A total of 47 patients underwent 53 procedures between 
January 2012 and January 2018, with 43 cases (81%) 
performed between March 2015 and January 2018 
(figure 2). The mean age ±SD was 57±15 years. Patients 
were predominantly male (68%) and Caucasian (81%). 
The aetiology of VT included nhVT (n=26, 49%), 
including right ventricular outflow (RVOT) (n=22), left 
ventricular outflow tract (n=2) and fascicular VT (n=2). 
shVT was common (n=27, 51%) and included ICM 
(n=19), dilated cardiomyopathy (n=5), hypertrophic 
cardiomyopathy (n=2) and valvular heart disease (n=1). 
Almost half of patients were referred locally (n=25, 47%), 
while the remainder were from our surrounding referral 
hospitals. Procedures were predominantly elective 
(66%). The median time from index VT presentation 
to VT ablation was 318 (122–654) days. Baseline patient 
characteristics are shown in table 1.
Hypertension, atrial fibrillation and heart failure were 
all more prevalent in the ICM group compared with 
nhVT. As expected, the left ventricular ejection fraction 
was significantly lower in the ICM group compared with 
the nhVT group (29%±1% vs 56%±6%; p=0.011). None 
of the patients with nhVT had an ICD, whereas the 
majority of patients with ICM had defibrillators (89%) 
and all had received therapies (94% ATP, 76% shocks). 
The most common antiarrhythmic agents included beta-
blockers (91%), amiodarone (43%), mexiletine (11%), 
verapamil (8%) and flecainide (2%). Only one patient 
with nhVT was treated with amiodarone compared with 
17 of 19 patients with ICM (89%). Mexiletine had been 
used in five patients with ICM and one patient with dilated 
cardiomyopathy. A significant proportion of patients 
were taking anticoagulation (39%): warfarin (25%) or 
apixaban (11%). Significantly more patients were antico-
agulated with ICM compared with nhVT (p=0.041).
Procedural data
A summary of the procedural data is shown in online 
supplementary table 1. All nhVT cases were performed 
under local anaesthesia and conscious sedation, with only 
4 of 19 ICM cases requiring general anaesthesia (21%). 
The majority of patients had two or more clinical VTs 
(87%), and most patients were in sinus rhythm at the 
start of the procedure (93%). Clinical VT was inducible 
or spontaneous in all patients with nhVT and 58% of 
patients with ICM. VT was haemodynamically stable in all 
patients with nhVT compared with less than two-fifths of 
patients with ICM (37%, p<0.001). The Abbott Velocity/
Precision mapping system was used in nearly two-thirds of 
cases, with CARTO 3 in the remainder. The most common 
multipolar mapping catheters included Pentaray (32%), 
HD linear Duodeca (21%) and the Array (19%).
Mapping was almost exclusively performed via the 
endocardial route (98%). The most common mapping 
strategies included pace mapping (68%), activation 
mapping (68%) and substrate mapping (57%); entrain-
ment mapping was performed less commonly (11%). In 
the ICM cohort all cases underwent substrate mapping, 
with additional 68% pace mapping, 22% entrainment 
mapping and 47% activation mapping. Pace mapping 
(when used) was successful in achieving an 11/12 ECG 
match in 94% of cases. Ablation catheters used included 
SmartTouch (30%), TactiCath (28%) and M Therapy 
(25%). For all cases the median radio frequency (RF) 
ablation time was 22 (IQR 11–48) min, while the median 
total procedural time was 200 (IQR 141–241) min. The 
median fluoroscopy time was 27 (19–34) min. The 
nhVT group had shorter RF ablation time (14 vs 56 min, 
p<0.001), overall procedural time (142 vs 240 min, 
p<0.001) and fluoroscopy times (21 vs 28 min, p=0.028) 
compared with ICM VT.
Outcomes
Acute procedural success occurred in 83% of all patients, 
with no significant difference between ICM and nhVT 
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Table 1 Baseline patient characteristics
All nhVT ICM P value
Procedures 53 26 19
Patients 47 23 16
Age, years 57±15 48±13 70±9 <0.001
Sex: male 36 (68) 15 (58) 14 (74) 0.268
Caucasian 43 (81) 18 (69) 18 (95) 0.035
Asian 3 (6) 8 (31) 1 (5)
Hypertension 14 (26) 2 (8) 10 (53) 0.002
Atrial fibrillation 12 (23) 1 (4) 8 (42) 0.002
Diabetes 4 (8) 1 (4) 2 (11) 0.375
Stroke 0     
Left ventricular systolic dysfunction (LVEF <40%) 21 (40) 0 15 (79) <0.001
LVEF, % 43±16 56±6 29±11 0.011
Wall motion abnormalities 22 (43) 1 (4) 17 (89) <0.001
Previous VT ablation 5 (9) 1 (4) 3 (16) 0.164
Implantable cardioverter defibrillator implanted 24 (45) 0 17 (89) <0.001
Device therapies received       
  ATP 22 (92) – 16 (94)
  Shock 16 (67) – 13 (76)
Beta-blocker 48 (91) 23 (88) 19 (100) 0.125
Amiodarone 23 (43) 1 (4) 17 (89) <0.001
Duration of amiodarone, median (IQR) months 12 (2–23) 12 9 (1–24)
Mexiletine 6 (11) 0 5 (26) 0.006
Verapamil 4 (8) 4 (15) 0 0.073
Flecainide 2 (4) 2 (8) 0 0.216
Anticoagulation 21 (39) 6 (23) 10 (53) 0.041
  Warfarin 13 (25) 5 (19) 7 (37)
  Apixaban 6 (11) 1 (4) 3 (16)
  Dabigatran 1 (2) 0 0
  Edoxaban 1 (2) 0 0
Values expressed as mean±SD or frequency (%) unless otherwise specified.
ATP, antitachycardia pacing; ICM, ischaemic cardiomyopathy; LVEF, left ventricular ejection fraction; nhVT, normal heart VT; VT, ventricular 
tachycardia.
(84% vs 85%, p=0.970). In total, six patients underwent 
redo procedures. All patients (n=47) were followed up for 
a median of 231 (133–631) days postprocedure. Sixteen 
patients with ICM were followed up for a median of 193 
(129–468) days, and 24 patients with nhVT were followed 
up for 358 days (134–358 days, p=0.205). The primary and 
secondary outcomes are shown in table 2. The primary 
outcome occurred in 13 patients (28%), with no signif-
icant difference between ICM and nhVT cases. Death 
occurred in two patients; however, these were non-ar-
rhythmic. Three of 16 (19%) patients suffered recurrent 
VT storm or appropriate shocks. Of the 13 patients with 
ICM who received shock therapy preprocedure, only 1 
(8%) patient received a recurrent shock. There were no 
significant differences in secondary outcomes between 
patients with ICM and nhVT. Procedural complication 
rates were low (11%) and included three pericardial effu-
sions not requiring intervention, one cardiac tamponade 
requiring pericardiocentesis, one cardiac perforation 
requiring emergency cardiac surgical repair with ster-
notomy and one groin haematoma managed conserva-
tively.
dIsCussIOn
The ventricular tachycardia ablation versus escalated 
antiarrhythmic drug therapy in ischemic heart disease 
(VANISH) trial demonstrated that catheter ablation in 
patients with drug refractory VT was effective in reducing 
the rate of VT storm and ICD shocks, with a reduction in 
the composite endpoint including death.7 Our real-world 
data show that catheter ablation for nhVT and shVT is 
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Table 2 Outcomes
All nhVT ICM P value
47 24 16
Primary outcome* 13 (28) 9 (38) 3 (19) 0.205
Secondary outcomes
  Cardiovascular 
hospitalisation
10 (21) 5 (21) 5 (31) 0.456
  Death 2 (4) 0 2 (13) 0.076
  Recurrent VT/shock 19 (40) 9 (38) 7 (44) 0.693
  VT storm† 4 (17) 3 (19)
  Appropriate shocks‡ 1 (2) 1 (6)
Values reported as frequency (%).
*The primary outcome for nhVT was a composite of all-cause 
death, cardiovascular hospitalisation and recurrent VT, defined as 
sustained VT or PVC burden >10%. For shVT the primary outcome 
was a composite of arrhythmic death, VT storm (≥3 VT episodes in 
24 hours) and appropriate shocks.
†Reported as a percentage of patients with SHD.
‡Reported as a percentage of patients with ICDs.
ICDs, implantable cardioverter defibrillators; ICM, ischaemic 
cardiomyopathy; nhVT, normal heart VT; PVC, premature 
ventricular contraction; SHD, structural heart disease; shVT, 
structural heart VT; VT, ventricular tachycardia.
relatively safe, and is associated with a high rate of acute 
procedural success and long-term success. The outcome 
of shVT ablation in our study was comparable with the 
VANISH trial’s primary outcome. In this multicentre 
RCT of 259 patients with ICM and recurrent VT despite 
AAD therapy, VT ablation was superior to escalating AAD 
therapy.7 In a meta-analysis of three RCTs including 346 
patients, VT ablation was found to reduce ICD therapies, 
including shocks and electrical storm, with no overall 
effect on mortality. Furthermore time to VT recurrence 
was significantly delayed in patients undergoing catheter 
ablation.6 7
The development and widespread availability of ICDs 
have resulted in a marked change in the survival of patients 
with VT.3 Patients who formerly would have succumbed 
to SCD now survive to experience recurrent VT episodes 
and ICD therapies. ICD therapy occurs in approximately 
40% of patients within the first year after ICD implant 
for secondary prevention20 21 and in 5%–18% of patients 
within 1 year after ICD implantation for primary preven-
tion.3 22 This, coupled with an increasing frequency of ICD 
implantation,23 24 has resulted in an increasing frequency 
of patients presenting with recurrent ICD shocks and the 
likelihood of a growing problem. Camm and Nisam23 
showed that implant rates for ICDs in the USA increased 
exponentially from 2003, and after a lag of 4 years VT abla-
tion rates have risen with a similar trend.14 UK data have 
shown an exponential rise in high energy implant rates 
from 2013, with 238 implants/million of the population 
in 2015/2016.24 Our registry data have shown a similar 
exponential rise in VT ablation cases since January 2016.
RCTs have recruited patients into large centres with 
extensive experience in VT ablation over several years. The 
VANISH trial was a multicentre RCT conducted at 22 tertiary 
centres where VT ablation was routinely performed, with 
centres chosen to reflect ‘a high level of competence in VT 
ablation technique’. We have shown that using the same 
patient selection criteria, an established regional centre 
can deliver a comparable clinical outcome of a relatively 
higher risk procedure with a safety profile comparable 
with nhVT ablation. The VANISH trial recruited patients 
treated with amiodarone for at least 3 months. Our cohort 
of patients with ICM included 15 of 16 (89%) patients 
treated with amiodarone for at least 9 months. Qualifying 
episodes of VT in VANISH were required to be monomor-
phic and to have a cycle length greater than 240 ms (250 
beats per minute), which was consistent with our cohort 
of patients with ICM (379±19 ms). In VANISH the primary 
outcome was a composite endpoint including death, VT 
storm or appropriate ICD shocks, which occurred less 
frequently in patients undergoing ablation versus patients 
having escalated AAD therapy (59.1% vs 68.5%, HR 0.72, 
95% CI 0.53 to 0.98, p=0.04). In our registry we report a 
primary outcome (arrhythmic death, VT storm or appro-
priate shocks) of 19% at a median of 6-month follow-up. 
When using the same primary outcome as in VANISH 
(all-cause death, VT storm or appropriate shocks) at 6 
months which was approximately 20%, we showed an 
event rate of 31%. Two large prospective multicentre trials 
reported acute success rates (defined as elimination of all 
inducible VTs) of 41% and 49% with long-term rates of 
freedom from VT of 44% and 53%, respectively.25 Our 
acute procedural endpoint performed in all patients with 
ICM demonstrated a procedural success rate of 84%. A 
strength of our study was the definition of acute proce-
dural success in ICM, based on data from Carbucicchio 
et al.13 It was shown that although elimination of all VTs 
(class A endpoint) provided the best outcome in terms 
of cardiac death, VT storm and any VT recurrence, the 
endpoint of clinical VT non-inducibility alone (class B 
endpoint) yielded a comparable cardiac death and recur-
rent VT storm primary outcome. The class B definition of 
success included residual VT with both longer and shorter 
cycle lengths to the clinical VT. Given that following abla-
tion recurrent VT is unlikely to present with a shorter 
TCL,26 we believe that our definition of success was more 
robust than the class B definition, as it included patients 
with successful ablation of clinical VT and all VTs with a 
longer TCL. This is further supported by the heart center 
of leipzig ventricular tacycardia (HELP-VT) registry data, 
where higher VT recurrence rates were observed in the 
class B defined cohort.27
Our outcomes for nhVT were comparable with a large 
multicentre retrospective study of 1185 patients under-
going catheter ablation of PVCs recruited over a 9-year 
period.28 With similar baseline characteristics to our 
cohort, Latchamsetty et al28 reported an acute procedural 
success rate of 84% and a long-term success rate of 85% 
after a mean of 1.9 years of follow-up.
Our study was not designed or powered to detect differ-
ences in mapping or ablation strategies. Various strategies 
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in VT ablation include targeting scar border zone with 
circumferential lines ± dense scar lines, scar homogenisa-
tion, LAVA/late potential sites, critical isthmus targeting 
and scar dechannelling. The VISTA (ventricular tachy-
cardia versus addition of substrate ablation on the long 
term success rate of VT ablation) trial compared clinical 
VT ablation versus substrate modification and showed 
better outcome in substrate-guided ablation.29 Both 
LAVA targeting9 and dechannelling8 have been shown 
to reduce recurrent VT. In haemodynamically unstable 
patients with VT, we routinely perform substrate-based 
ablation targeting border zones and LAVA/late poten-
tials, and in more recent cases we adopted the dechannel-
ling protocol which has yielded excellent non-inducibility 
endpoints. Technological advances in ablation lesion 
assessment over the course of the study resulted in 
increased use of force-time integral, lesion size index and 
ablation index in more recent cases.
A further strength of our study is that we reported 
rates of procedures performed under conscious sedation 
or general anaesthesia. Given the limited catheter labo-
ratory time and general anaesthetic cover which most 
UK tertiary centres are challenged with, a predominate 
substrate mapping strategy has enabled the majority of 
our procedures to be safely performed under conscious 
sedation with procedural times reduced to less than 
4 hours, requiring on average of 28 min of fluoroscopy 
and 56 min of ablation, comparable with the HELP-VT 
registry data.27
The high efficacy and safety outcomes reported in our 
real-world registry data reflect a combination of local 
expertise and a range of facilities in our established elec-
trophysiology (EP) centre. Catheter ablation for VT can 
be complex and associated with an increased mortality 
risk when performed in low-volume or medium-volume 
centres (<25 postinfarct VT ablation procedures per 
year).14 In a European survey of 88 centres in 12 countries, 
approximately 22% and 14% of centres perform more 
than 50 VT ablations per year for patients with normal 
heart and SHD, respectively.30 Readers are directed to a 
recent international expert consensus statement on cath-
eter ablation of ventricular arrhythmias, which sets out 
requirements for operators and institutions to ensure 
ablations can be performed competently and safely.31 
Briefly electrophysiologists should be adequately trained 
in mapping and ablation of complex ventricular arrhyth-
mias. Institutions should have adequate facilities and 
personnel, including onsite interventional cardiologists 
(for coronary imaging); onsite cardiothoracic surgical 
backup for procedures requiring pericardial access in 
cases of the need for emergency sternotomy and cardio-
pulmonary bypass; and anaesthetic support.
study limitations
This study is a single-centre, non-randomised cohort 
and represents the skills of six experienced operators. 
The mapping and ablation strategies employed were not 
predefined but rather reflected contemporary trends in 
techniques and technology. It is possible that the combina-
tion of technological advances and a ‘learning curve’ may 
account for better outcomes in the ICM group compared 
with the nhVT, which were predominantly performed 
in the early stages of our VT ablation service. Finally, in 
our study we did not include outcomes following repeat 
ablations for recurrent VT. During the study period we 
performed two ablation procedures in six patients, which 
may have resulted in improved outcomes than those 
reported in this present study.
COnClusIOn
These real-world registry data have demonstrated that 
catheter ablation for VT is safe and effective, with acute 
procedural and long-term outcomes comparable with 
RCTs. Furthermore, in our cohort we found similar 
safety and efficacy for VT ablation in patients with ICM 
and nhVT. Our study shows that using the same patient 
selection criteria as the VANISH trial, an established abla-
tion centre can deliver an equivalent clinical outcome 
of a relatively higher risk procedure (ie, ICM VT cath-
eter ablation) with a good safety profile comparable with 
nhVT.
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